=================================
OMB APPROVAL
=================================
OMB Number: 3235-0145
=================================
Expires: October 31, 2002
=================================
Estimated average burden
hours per response. . . 14.9
=================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Arena Pharmaceuticals, Inc.
----------------------------------------------------------------------------
(Name of Issuer)
Common Stock
----------------------------------------------------------------------------
(Title of Class of Securities)
040047102
----------------------------------------------------------------------------
(CUSIP Number)
December 31, 2001
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. ..... 040047102.............
..............................................................................
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
International BM Biomedicine Holdings AG
..............................................................................
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ................................................................
(b) ................................................................
3. SEC Use Only .......................................................
4. Citizenship or Place of Organization... Basel, Switzerland...........
..............................................................................
Number of 5. Sole Voting Power .........1,034,665........................
Shares
Beneficially ................................................................
Owned by 6. Shared Voting Power .......None.............................
Each
Reporting 7. Sole Dispositive Power.....1,034,665........................
Person With ................................................................
8. Shared Dispositive Power ...None ...........................
9. Aggregate Amount Beneficially Owned by Each Reporting Person
...1,034,665.........................................................
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)...................................................
11. Percent of Class Represented by Amount in Row (9) ....3.75%..........
12. Type of Reporting Person (See Instructions)
.................................CO...........................................
..............................................................................
Item 1.
(a) Name of Issuer: Arena Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices
6166 Nancy Ridge Drive, San Diego, CA 92121
Item 2.
(a) Name of Person Filing: International BM Biomedicine Holdings AG
(b) Address of Principal Business Office or, if none, Residence
Nauenstrasse 41, P.O. Box 4002, Basel, Switzerland
(c) Citizenship: Switzerland
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number 040047102
Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the Act
(15 U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C.
78c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c).
(d) [ ] Investment company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C 80a-8).
(e) [ ] An investment adviser in accordance with section
240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance
with section 240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance
with section 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
Item 4. Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: ________1,034,665________________.
(b) Percent of class: 3.75%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote ______1,034,665.
(ii) Shared power to vote or to direct the vote none.
(iii) Sole power to dispose or to direct the disposition of 1,034,665.
(iv) Shared power to dispose or to direct the disposition of none.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following [x].
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on By the Parent Holding Company
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired
and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose
or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and
correct.
February 14, 2002
--------------------------------
Date
/s/ Dr. Gaudenz I. Staehelin
--------------------------------
Signature
Dr. Gaudenz I. Staehelin/Vice Chairman
--------------------------------
Name/Title
/s/ Patrick Weber
--------------------------------
Signature
Patrick Weber/CEO
--------------------------------
Name/Title